Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 7630 · · 10 pages · English
Summary by 6ix AI
It confirms the total authorized and registered share capital at the end of the month. The report also includes information on issued shares and public float sufficiency confirmation. The filing indicates that there were no changes in the number of issued shares during the month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
IMPACT Therapeutics, Inc. on 6ix
Earlier from IMPACT Therapeutics
- Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
- 2026 Interim Report
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
- Articles of association
- Next Day Disclosure Return
Later from IMPACT Therapeutics
All IMPACT Therapeutics news releasesFollow IMPACT Therapeutics into a list and get an email when it puts out news.
Follow IMPACT Therapeutics